3 Results for "

LSD1/HDAC-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "LSD1/HDAC-IN-2" in MCE Product Catalog:

Cat. No.: HY-169938
CAS No.: 2966782-82-9
Research Areas:  

Cancer

LSD1/HDAC-IN-2 (Compound 20c) is the inhibitor for LSD and HDAC, that inhibits LSD1, HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, with IC50s of 39.0, 1.4, 1.0, 1.3, 2.9 and 16.0 nM, respectively. LSD1/HDAC-IN-2 inhibits the proliferation of cancer cells, especially the colorectal cancer cells. LSD1/HDAC-IN-2 arrests the cell cycle at G2/M phase, inhibits cell migration, and induces apoptosis in HCT-116 and HT-29 cells. LSD1/HDAC-IN-2 exhibits antitumor efficacy in mouse model without significant toxicity [1].
loading...
    loading...
Cat. No.: HY-145259
CAS No.: 3023019-99-7
Purity:  ≥98.0%
Research Areas:  

Cancer

HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC50s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC50=0.79 μM) and LSD1 inhibitor [1]. HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-187092
CAS No.: 1423715-30-3
Target:  

Histone Demethylase

Research Areas:  

Cancer

LSD1-IN-51 is a selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 8.7 nM. LSD1-IN-51 selectively inhibits H3K4me1/2 demethylation by binding to the FAD domain of LSD1, while disrupting the interaction between LSD1 and multiprotein complexes such as HDAC1/2 and CoREST. LSD1-IN-51 can be used for cancer research [1].
loading...
    loading...